HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Wagner, P. D. Search for Related Content PubMed PubMed Citation Articles by Wagner, P. D.

Possible mechanisms underlying the development of cachexia in COPD

Division of Physiology, Dept of Medicine, University of California, San Diego, La Jolla, CA, USA.

CORRESPONDENCE: P. D. Wagner, Division of Physiology, Dept of Medicine, University of California, San Diego, 9500 Gilman Drive, DEPT 0623A, La Jolla, CA 92093-0623A, USA. Fax: 1 8585344812. E-mail: pdwagner{at}ucsd.edu

Keywords: Cachexia, chronic obstructive pulmonary disease

Received: July 20, 2007
Accepted September 4, 2007

About 25% of patients with chronic obstructive pulmonary disease (COPD) will develop cachexia (fat-free body mass index <17 kg·m^–2 (males) or <14 kg·m^–2 (females)). This is associated with 50% reduction in median survival.

The pathogenetic mechanism has been variously suggested to result from the following: 1) energy imbalance; 2) disuse atrophy; 3) tissue hypoxia from arterial hypoxaemia; 4) systemic inflammation; and 5) anabolic hormonal insufficiency. Genetic polymorphisms implicate inflammatory cytokines, especially interleukin (IL)-1β, but IL-6 and tumour necrosis factor (TNF)- do not show polymorphisms in these patients. Early reports of elevated TNF- levels suggested a role for inflammation, but recent studies have not shown elevated levels of either IL-6 or TNF-. Therapeutic trials of nutritional support, hormonal supplementation, anti-TNF- immunotherapy, ghrelin and antioxidants have been conducted, but only a few have shown any benefits in muscle structure and function.

Considerably more mechanistic knowledge is needed before therapeutic recommendations can be made. At this time, it is not possible to attribute cachexia in COPD unequivocally to inflammation or any other cause, and much more research is needed.

To date, studies have been predominantly cross-sectional, with measurements made only after cachexia has developed. Future research should target prospective observation, studying patients as cachexia progresses, since once cachexia is established, inflammatory cytokine levels may not be abnormal.

This article has been cited by other articles:

				M.-A. Caron, R. Debigare, P. N. R. Dekhuijzen, and F. Maltais Comparative assessment of the quadriceps and the diaphragm in patients with COPD J Appl Physiol, September 1, 2009; 107(3): 952 - 961. [Abstract] [Full Text] [PDF]

				A. Vigano, B. Trutschnigg, R. D. Kilgour, N. Hamel, L. Hornby, E. Lucar, W. Foulkes, M. L. Tremblay, and J. A. Morais Relationship Between Angiotensin-Converting Enzyme Gene Polymorphism and Body Composition, Functional Performance, and Blood Biomarkers in Advanced Cancer Patients Clin. Cancer Res., April 1, 2009; 15(7): 2442 - 2447. [Abstract] [Full Text] [PDF]

				Z. Wang, C. Zhao, R. Moya, and J. D. Davies A Novel Role for CD4+ T Cells in the Control of Cachexia J. Immunol., October 1, 2008; 181(7): 4676 - 4684. [Abstract] [Full Text] [PDF]

				H. J. Green, M. E. Burnett, C. L. D'Arsigny, D. E. O'Donnell, J. Ouyang, and K. A. Webb Altered metabolic and transporter characteristics of vastus lateralis in chronic obstructive pulmonary disease J Appl Physiol, September 1, 2008; 105(3): 879 - 886. [Abstract] [Full Text] [PDF]